Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd … – Pharmaceutical Processing
Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd …Pharmaceutical Processing13,14 Inotuzumab is currently being evaluated in a Phase 3 study in combination with rituximab in patients with relapsed or refractory CD22-positive a…